Molecular Partners Future Growth

Future criteria checks 2/6

Molecular Partners is forecast to grow earnings and revenue by 5.1% and 43.8% per annum respectively. EPS is expected to grow by 2.9% per annum. Return on equity is forecast to be -128.6% in 3 years.

Key information

5.1%

Earnings growth rate

2.9%

EPS growth rate

Biotechs earnings growth	19.6%
Revenue growth rate	43.8%
Future return on equity	-128.6%
Analyst coverage	Low
Last updated	19 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0QXX - Analysts future estimates and past financials data (CHF Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	18	-81	-85	-61	2
12/31/2025	19	-62	-71	-43	2
12/31/2024	14	-60	-67	-56	2
12/31/2023	7	-62	-60	-59	N/A
9/30/2023	9	-60	-58	-57	N/A
6/30/2023	9	-62	-63	-62	N/A
3/31/2023	20	-50	-63	-62	N/A
12/31/2022	190	118	117	119	N/A
9/30/2022	189	117	112	114	N/A
6/30/2022	190	118	111	113	N/A
3/31/2022	182	106	101	102	N/A
12/31/2021	10	-64	-92	-91	N/A
9/30/2021	9	-67	-71	-69	N/A
6/30/2021	6	-72	-55	-54	N/A
3/31/2021	7	-66	-47	-46	N/A
12/31/2020	9	-63	-31	-29	N/A
9/30/2020	11	-53	-47	-45	N/A
6/30/2020	14	-48	-58	-56	N/A
3/31/2020	17	-43	-30	-28	N/A
12/31/2019	20	-36	-3	-1	N/A
9/30/2019	17	-37	0	1	N/A
6/30/2019	14	-38	2	4	N/A
3/31/2019	12	-38	-20	-19	N/A
12/31/2018	10	-37	-43	-42	N/A
9/30/2018	17	-27	-41	-41	N/A
6/30/2018	23	-18	-39	-39	N/A
3/31/2018	22	-24	N/A	N/A	N/A
12/31/2017	20	-25	-41	-40	N/A
9/30/2017	17	-26	N/A	N/A	N/A
6/30/2017	16	-28	N/A	-38	N/A
3/31/2017	19	-22	N/A	N/A	N/A
12/31/2016	23	-19	N/A	-35	N/A
9/30/2016	27	-13	N/A	N/A	N/A
6/30/2016	31	-3	N/A	18	N/A
3/31/2016	30	-2	N/A	N/A	N/A
12/31/2015	29	0	N/A	26	N/A
9/30/2015	28	-6	N/A	N/A	N/A
6/30/2015	25	-11	N/A	-24	N/A
3/31/2015	26	-5	N/A	N/A	N/A
12/31/2014	27	-2	N/A	-11	N/A
12/31/2013	32	7	N/A	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0QXX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0QXX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0QXX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0QXX's revenue (43.8% per year) is forecast to grow faster than the UK market (3.4% per year).

High Growth Revenue: 0QXX's revenue (43.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0QXX is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Molecular Partners Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2022

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Recent updates

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Molecular Partners AG Announces Executive Changes

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CHF3.63 (vs CHF2.06 loss in FY 2021)

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

High number of new directors

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Third quarter 2022 earnings released: CHF0.41 loss per share (vs CHF0.38 loss in 3Q 2021)

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Second quarter 2022 earnings released: CHF0.14 loss per share (vs CHF0.56 loss in 2Q 2021)

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

First quarter 2022 earnings released: EPS: CHF4.74 (vs CHF0.57 loss in 1Q 2021)

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Third quarter 2021 earnings released: CHF0.38 loss per share (vs CHF0.67 loss in 3Q 2020)

Forecast to breakeven in 2022

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Second quarter 2021 earnings released: CHF0.56 loss per share (vs CHF0.52 loss in 2Q 2020)

Forecast to breakeven in 2021

Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for ensovibep for the Treatment of COVID-19

Director has left the company

New 90-day low: CHF20.65

Revenue misses expectations

Full year 2020 earnings released: CHF2.51 loss per share (vs CHF1.70 loss in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day high: CHF23.25

Molecular Partners AG to Report Fiscal Year 2020 Results on Feb 26, 2021

New 90-day high: CHF25.20

New 90-day high: CHF25.20

New 90-day high: CHF25.20

Novartis AG (SWX:NOVN) acquired 6% stake in Molecular Partners AG (SWX:MOLN) for CHF 30 million.

Novartis Announces Collaboration with Molecular Partners AG to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19

New 90-day low: CHF15.60

Earnings released

Molecular Partners AG to Report Q1, 2021 Results on May 12, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies